Regulus Therapeutics (RGLS) to Release Quarterly Earnings on Thursday

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.20) EPS for the quarter, meeting the consensus estimate of ($0.20). During the same period last year, the business posted ($0.40) earnings per share. On average, analysts expect Regulus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Regulus Therapeutics Stock Performance

RGLS remained flat at $7.85 on Friday. 3,074,685 shares of the company traded hands, compared to its average volume of 869,941. The stock's 50-day simple moving average is $2.11 and its two-hundred day simple moving average is $1.66. Regulus Therapeutics has a 12-month low of $0.83 and a 12-month high of $8.20. The stock has a market cap of $520.01 million, a price-to-earnings ratio of -7.34 and a beta of 1.03.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Wells Fargo & Company reiterated an "equal weight" rating and issued a $9.00 target price on shares of Regulus Therapeutics in a report on Thursday. Jones Trading reissued a "hold" rating and set a $7.00 target price (down previously from $8.00) on shares of Regulus Therapeutics in a research note on Wednesday. Canaccord Genuity Group reaffirmed a "hold" rating and issued a $11.00 target price (down from $28.00) on shares of Regulus Therapeutics in a research report on Wednesday. Leerink Partners restated a "market perform" rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a report on Wednesday. Finally, HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Regulus Therapeutics in a report on Friday, March 14th. One analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $8.50.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.